Fulgent Genetics/$FLGT
Fulgent Genetics shares rise after Q3 revenue and adjusted loss beat expectations and the company improved its FY26 loss outlook as billing collections recovered.
16 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
- Ticker
- $FLGT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,315
- Headquarters
- El Monte, United States
- Website
- www.fulgentgenetics.com
Fulgent Genetics Metrics
BasicAdvanced
$663M
-
-$3.10
1.02
-
Price and volume
Market cap
$663M
Beta
1.02
52-week high
$31.04
52-week low
$13.46
Average daily volume
306K
Financial strength
Current ratio
5.339
Quick ratio
5.035
Long term debt to equity
0.008
Total debt to equity
0.011
Interest coverage (TTM)
-1,237.21%
Profitability
EBITDA (TTM)
-95.88
Gross margin (TTM)
33.82%
Net profit margin (TTM)
-27.53%
Operating margin (TTM)
-37.09%
Effective tax rate (TTM)
7.07%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-6.68%
Return on equity (TTM)
-8.74%
Valuation
Price to revenue (TTM)
2.111
Price to book
0.67
Price to tangible book (TTM)
0.83
Price to free cash flow (TTM)
-498.101
Free cash flow yield (TTM)
-0.20%
Free cash flow per share (TTM)
-0.048
Growth
Revenue change (TTM)
4.67%
Earnings per share change (TTM)
120.66%
3-year revenue growth (CAGR)
4.86%
10-year revenue growth (CAGR)
35.94%
3-year earnings per share growth (CAGR)
13.13%
10-year earnings per share growth (CAGR)
5.60%
What the Analysts think about Fulgent Genetics
Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.
Analyst projections of the future price of Fulgent Genetics stock.
Bulls say / Bears say
Anatomic pathology is expanding quickly: third-quarter revenue rose 57% year on year to $40.9 million, supported by the Bako and StrataDx businesses and their broader sales reach. Cross-selling and applying Fulgent’s AI tools to this larger operation could support further growth and efficiency. (Fulgent Genetics, The Motley Fool)
Collections improved in the third quarter, and Fulgent raised its full-year non-GAAP loss forecast to $46–50 million from $63–67 million. If the billing fixes hold, that points to a better near-term financial trajectory. (Fulgent Genetics, The Motley Fool)
Fulgent has held an FDA end-of-Phase-2 meeting for FID-007 and is preparing a Phase 3 study, while FID-022 is progressing through Phase 1. Positive trial progress could create a longer-term growth opportunity beyond diagnostic testing. (The Motley Fool)
Fulgent remains loss-making, with a third-quarter GAAP net loss of $13.2 million versus $6.6 million a year earlier and an operating loss of $22.5 million versus $15.4 million. Continued losses leave the business needing to improve margins and collections. (Fulgent Genetics, The Motley Fool)
Headline revenue growth masks weakness in the core precision diagnostics business: third-quarter revenue there fell 18% year on year to $41.8 million, while total 2026 revenue guidance implies only 2.3%–5.4% growth. That makes the growth outlook reliant on other services and acquisitions. (The Motley Fool)
The changeover to Fulgent’s billing and revenue-cycle system delayed claims processing and weakened collection rates, prompting a reduction in 2026 revenue guidance earlier in the year. Management says collections are improving, but the timing and durability of a full recovery remain uncertain. (Fulgent Genetics, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Fulgent Genetics Financial Performance
Revenues and expenses
Fulgent Genetics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Fulgent Genetics News
AllArticlesVideos
Funds containing Fulgent Genetics
Fund name | Fund size | $FLGT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.